About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.

Older adults experiencing irreversible blindness may now be able to see thanks to a system relying on a wireless retinal implant and high-tech glasses ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

One of the most pernicious conditions that afflicts around five million people worldwide is “geographic atrophy,” or GA, an advanced form of dry age-related macular degeneration that is one of the ...

Genomics company Illumina (NASDAQ:ILMN) in Q3 CY2025, but sales were flat year on year at $1.08 billion. Its non-GAAP profit of $1.34 per share was 14.7% above analysts’ consensus estimates. Is now ...

According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...

A photovoltaic retinal implant shows promise as a way to improve vision in patients with advanced age-related macular ...

Thank you, Sabrina, and good morning, everyone. The third quarter was another exceptional quarter for GeneDx. Achieving that vision requires a fast-growing, disciplined, profitable business that ...

The manuscript concerns a fundamental and controversial question in Trypanosoma brucei biology and the parasite life cycle, providing further evidence that slender bloodstream forms can indeed infect ...

A new trial shows that a wireless subretinal implant, the PRIMA system, restored central vision in patients with geographic ...